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agreement with ICE results in all ten. Nine (9) of ten (10) patients with TCD-negative
RLS, had SCI  0.
Conclusions: The Cardiox FDS, with the established dosage of ICG dye and timing
protocols, provided consistent detection of significant RLS (Spencer Grades IV or V),
with a good negative predictive value.
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Background: Percutaneous closure of ASD/ PFO has become a common procedure.
Concerns exist regarding possible adverse outcomes with device implantation in patients
allergic to nickel. Quantifying nickel elution by various devices is important.
Methods: We compared nickel elution behavior of 4 devices- AGA Amplatzer®
Occluder “Cribriform” (AGA Medical Corporation; Plymouth, Minn), Gore GSO® and
Gore Helex® Septal Occluder (W.L.Gore & Associates, Flagstaff, AZ), Sternalwire, and
control-1xDulbecco’s Phosphate-Buffered Saline (DPBS). Three device samples from
each group were submerged in DPBS. Nickel elution was measured by blinded personal
using Plasma Mass Spectroscopy at 24hours (h), 48h, 72h then weekly to 60 days.
Results: Nickel elution was significantly higher for AGA device compared to control
group at all time points to 60 days (15.202.89 vs0.010mg/L, p.001,Figure1).
Individual group comparisons by Bonferroni Multiple Comparisons test showed that
nickel elution was statistically similar amongst devices other than AGA.
Conclusions: There is significant variability of Nickel elution among the intra-atrial
septal closure devices. AGA device has the greatest Nickel elution over 60 days. Clinical
significance of nickel elution needs to be evaluated in clinical studies.
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Background: Paradoxical cerebral embolic events via PFO are well described.The
frequency and impact of such embolization to other vascular beds is poorly defined.We
describe a single center cohort of patients presenting with non-cerebrovascular paradox-
ical emboli,evaluating the relationship between high-risk PFO echo features,previously
undiagnosed May-Thurner Syndrome,and hypercoagulability(cohort 1)compared to pa-
tients presenting with stroke(CVA)and/or transient ischemic attack(TIA)(cohort 2).
Methods: 801 patients who underwent transcatheter closure of PFO between 2001 and
2010 were retrospectively analyzed with clinical,procedural characteristics plus immedi-
ate and long-term follow-up recorded.Two-sided T tests and Fishers’Exact test and
Kaplan-Meier event free (death,cardiac death,CVA/TIA,arterial embolic event)survival
analysis were performed.
Results: 801 closures were performed.Cohort 1 included 29 PFO closures(3.5% of
total),with 6 acute myocardial infarctions (MI),9 retinal emboli,6 renal infarctions,3 radial
artery occlusions,3 splenic infarcts, and 2lower extremity arterial emboli.772 patients are
included in cohort 2.Cohort 1 had a higher incidence of May-Thurner
syndrome(p0.0005)and were more likely to have an atrial septal aneurysm(p
0.08).Procedural success was 100%.In-hospital 1 device embolization was successfully
retrieved,no other in-hospital complications occurred.Effective defect closure was 100%
with no significant residual shunting.Event-free survival in cohort 1 was 100%, median
follow-up of 12.1 months (IQR 4.7, 23.7) compared with 97.4%, median follow-up of
25.3 months(IQR 11.6, 57.8) in cohort 2.
Risk Factor Cohort 1 (N 29) Cohort 2 (N 772) p-Value
Age mean (SD) 48.0 (	/14) 49.9 (	/13.7) 0.8
Male Gender 50% 53.5% 0.8
Hypertension 33.3% 30.0% 0.8
Hyperlipidemia 47.6% 34.9% 0.3
Current or former Smoker 25.0% 34.2% 0.3
Family Hx of vascular
disease
0 10.4 0.1
Diabetes 4.2% 5.7% 0.7
Hypercoagulable Disorder 33.3% 27.5% 0.5
Echo Tunnel Length (mm) 8.2 (	/ 4.4) 11.1 (	/4.7) 0.9
Atrial Septal Aneursym 41.7% 25.5% 0.08
May-Thurner Syndrome 41.7% 15.1% 0.0005
Conclusions: This is the largest series of PFO associated non-CVA/TIA paradoxical
emboli,highlighting the need to screen for high risk PFO features and co-existantMay-
Thurner syndrome.These patients can be treated successfully with transcatheter closure,
with no recurrent events in follow-up.
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Background: Percutaneous transcatheter closure of patent foramen ovale (PFO) is com-
monly performed for several indications despite conflicting data regarding the efficacy of this
intervention. We examined the indications for as well as the immediate and long-term
procedural outcomes of PFO closure in a large and diverse cohort of patients.
Methods: We report the outcomes of 801 consecutive patients (52% male, 5014 years)
who underwent PFO closure at our institution over a 13-year period after rigorous
multidisciplinary evaluation.
Results: Indications for closure included cryptogenic cerebrovascular event (93%), hypox-
emia (2%), peripheral embolism (3%), and other (2%). Procedural success was 99% with
effective closure obtained in 95% of patients. At a mean follow-up of 3635 months, 20
patients sustained a recurrent neurologic event (6 strokes, and 14 transient ischemic attacks) for
a cumulative incidence rate of 0.83% per year (Figure). Only Eustachian valve prominence
(hazard ratio (HR)12.5 (95% confidence interval: 3.56–43.6); p-value0.0001) and
moderate or severe residual shunt after closure (HR5.36 versus no or trace shunt (95%CI:
1.21–23.85); p-value0.03) were associated with neurologic events.
Conclusions: Transcatheter closure of PFO is safe and feasible in patients with several
clinical indications. The efficacy of this intervention in patients with paradoxical
embolism appears superb in this long-term observational study. Carefully selected patients
with features suggestive of paradoxical embolism are the most likely to benefit from PFO
closure and should be the focus of future investigation.
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